TY - JOUR
T1 - Simultaneous measurement of 92 serum protein biomarkers for the development of a multiprotein classifier for ovarian cancer detection
AU - Skubitz, Amy P.N.
AU - Boylan, Kristin L.M.
AU - Geschwind, Kate
AU - Cao, Qing
AU - Starr, Timothy K.
AU - Geller, Melissa A.
AU - Celestino, Joseph
AU - Bast, Robert C.
AU - Lu, Karen H.
AU - Koopmeiners, Joseph S.
N1 - Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019/3
Y1 - 2019/3
N2 - The best known ovarian cancer biomarker, CA125, is neither adequately sensitive nor specific for screening the general population. By using a combination of proteins for screening, it may be possible to increase the sensitivity and specificity over CA125 alone. In this study, we used Proseek Multiplex Oncology II plates to simultaneously measure the expression of 92 cancer-related proteins in serum using proximity extension assays. This technology combines the sensitivity of the PCR with the specificity of antibodybased detection methods, allowing multiplex biomarker detection and high-throughput quantification. We analyzed 1 μL of sera fromeach of 61 womenwith ovarian cancer and compared the values obtained with those from 88 age-matched healthy women. Principle component analysis and unsupervised hierarchical clustering separated the ovarian cancer patients from the healthy, with minimal misclassification. Data from the Proseek plates for CA125 levels exhibited a strong correlation with clinical values for CA125. We identified 52 proteins that differed significantly (P < 0.006) between ovarian cancer and healthy samples, several of which are novel serum biomarkers for ovarian cancer. In total, 40 proteins had an estimated area under the ROC curve of 0.70 or greater, suggesting their potential to serve as biomarkers for ovarian cancer. CA125 alone achieved a sensitivity of 93.4% at a specificity of 98%. By adding the Oncology II values for five proteins to CA125 in a multiprotein classifier, we increased the assay sensitivity to 98.4% at a specificity of 98%, thereby improving the sensitivity and specificity of CA125 alone.
AB - The best known ovarian cancer biomarker, CA125, is neither adequately sensitive nor specific for screening the general population. By using a combination of proteins for screening, it may be possible to increase the sensitivity and specificity over CA125 alone. In this study, we used Proseek Multiplex Oncology II plates to simultaneously measure the expression of 92 cancer-related proteins in serum using proximity extension assays. This technology combines the sensitivity of the PCR with the specificity of antibodybased detection methods, allowing multiplex biomarker detection and high-throughput quantification. We analyzed 1 μL of sera fromeach of 61 womenwith ovarian cancer and compared the values obtained with those from 88 age-matched healthy women. Principle component analysis and unsupervised hierarchical clustering separated the ovarian cancer patients from the healthy, with minimal misclassification. Data from the Proseek plates for CA125 levels exhibited a strong correlation with clinical values for CA125. We identified 52 proteins that differed significantly (P < 0.006) between ovarian cancer and healthy samples, several of which are novel serum biomarkers for ovarian cancer. In total, 40 proteins had an estimated area under the ROC curve of 0.70 or greater, suggesting their potential to serve as biomarkers for ovarian cancer. CA125 alone achieved a sensitivity of 93.4% at a specificity of 98%. By adding the Oncology II values for five proteins to CA125 in a multiprotein classifier, we increased the assay sensitivity to 98.4% at a specificity of 98%, thereby improving the sensitivity and specificity of CA125 alone.
UR - http://www.scopus.com/inward/record.url?scp=85062419570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062419570&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-18-0221
DO - 10.1158/1940-6207.CAPR-18-0221
M3 - Article
C2 - 30709840
AN - SCOPUS:85062419570
SN - 1940-6207
VL - 12
SP - 171
EP - 183
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 3
ER -